HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

Christina Mattina

Articles

JAMA Commentary Urges Realistic View of New CAR T-Cell Cancer Therapy

September 25, 2017

While the FDA’s approval of the immunotherapy tisagenlecleucel represents a landmark in the oncology field, the treatment is far from being a cure and should be viewed in context of its $475,000 price tag, a group of oncologists wrote in a commentary published in JAMA.

Immune Adverse Events From Nivolumab Predict Better Survival With NSCLC

September 23, 2017

When immune-related adverse events arise from nivolumab, it may indicate that the therapy is having greater efficacy against non—small-cell lung cancer (NSCLC), as a new study demonstrates a link between these events and improved survival outcomes.

Representatives Probe CMS for Further Detail on New CAR-T Therapy Payment Agreement

September 14, 2017

After CMS and Novartis devised an outcomes-based payment approach for the new chimeric antigen receptor (CAR)-T treatment tisagenlecleucel (Kymriah), a group of representatives are requesting more information on the specifics of the agreement.

Gilead Sciences Announces $11.9 Billion Purchase of CAR-T Developer Kite Pharma

August 28, 2017

Gilead Sciences will acquire Kite Pharma by the end of 2017 in an $11.9 billion transaction that will place Gilead at the forefront of chimeric antigen receptor-T (CAR-T) cell therapy development.

Kite's CAR-T Therapy Produces Durable Remission in DLBCL, Study Finds

July 24, 2017

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

Ibrutinib Prevents Cytokine-Release Syndrome After CAR T-Cell Therapy for B-Cell Neoplasms

January 18, 2017

A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not treated with ibrutinib.